Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A

International Journal of Pharmaceutics

Volumn 249, Issue 1-2, 2002, Pages 101-108

  El Shabouri, M H ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Bioavailability; Chitosan; Cyclosporin; Nanoparticles; Positively charged

Indexed keywords

CHITOSAN; CYCLOSPORIN A; DRUG VEHICLE; GLYCOCHOLATE SODIUM; HYDROCHLORIC ACID; NANOPARTICLE; PHOSPHATIDYLCHOLINE; POLOXAMER; SEACURE CL 210; UNCLASSIFIED DRUG; CYCLOSPORIN;

ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CHEMICAL PROCEDURES; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG POTENTIATION; ELECTRICITY; EMULSIFICATION SOLVENT DIFFUSION METHOD; EMULSION; ENCAPSULATION; LIPOPHILICITY; MALE; MICROEMULSION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL; ANIMAL; BLOOD; CHEMISTRY; COMPARATIVE STUDY; METHODOLOGY; NANOTECHNOLOGY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DOGS; MALE; NANOTECHNOLOGY;

EID: 0037027833     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(02)00461-1     Document Type: Article

References (39)

1. Artursson P., Lindmark T., Davis S.S., Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11:1994;1358-1361.
2. Borel J.F., Gunn H.C. Cyclosporin as a new approach to therapy of autoimmune diseases. Ann. New York Acad. Sci. 457:1986;307-319.
3. Calvo P., Vila-Jato J.L., Alonso M.J. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int. J. Pharm. 153:1997;41-50.
4. Cavanak T., Sucker H. Formulation of dosage forms. Prog. Allergy. 38:1986;65-72.
5. Davis J.T., Rideal E.K. Interfacial Phenomena. 1963;Academic Press, New York.
6. Elbaz E., Zeevi A., Klang S., Benita S. Positively charged submicron emulsions - a new type of colloidal drug carrier. Int. J. Pharm. 96:1993;R1-R6.
7. Ford J., Woolfe J., Florence A.T. Nanospheres of cyclosoprin A: poor oral absorption in dogs. Int. J. Pharm. 183:1999;3-6.
8. Gershanik T., Benita S. Positively charged self-emulsifying oily formulation for improving oral bioavailability of progesterone. Pharm. Dev. Technol. 1:1996;147-157.
9. Gershanik T., Haltner E., Lehr C.M., Benita S. Charge-dependent interaction of self-emulsifying oily formulations with Caco-2 cells monolayers: binding effects on barrier function and cytotoxicity. Int. J. Pharm. 211:2000;29-36.
10. Gibaldi M., Perrier D. Pharmacokinetics. 1982;Marcel Dekker, New York.
11. Guo L.S.S., Radhakrishnan R., Redemann C.T. Adhesion of positively charged liposomes to mucosal tissues. J. Liposomal Res. 1:1989;319-337.
12. Guzmán M., Molpeceres J., Garciá F., Aberturas M.R., Rodriguez M. Formation and characterization of cyclosporin-loaded nanoparticles. J. Pharm. Sci. 82:1993;498-502.
13. Illum L., Farraj N.F., Davis S.S. Chitosan as a novel nasal delivery system for peptide drugs. Pharm. Res. 11:1994;1186-1189.
14. Ismailos G., Reppas C., Dressman J.B., Macheras P. Unusual solubility behavior of cyclosporin A in aqueous media. J. Pharm. Pharmacol. 43:1991;287-289.
15. Kovarik J.M., Mueller E.A., Van Bree J.B., Tetzloff W., Kutz K. Reduced inter- and intra-individual variability in cyclosporin pharmacokinetics from a microemulsion formulation. J. Pharm. Sci. 83:1994;444-446.
16. Kozté A.F., Lueßen H.L., Leeuw B.J., Boer A.G., Verhoef J.C., Junginger H.E. Comparison of the effect of different chitosan salts and N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). J. Control. Release. 51:1998;35-46.
17. Kozté A.F., Thanou M.M., Lueßen H.L., Boer A.G., Verhoef J.C., Junginger H.E. Effect of degree of quaternization of N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). Eur. J. Pharm. Biopharm. 47:1999;269-274.
18. Lee M., Choi L., Kim M., Kim C. Pharmacokinetics and organ distribution of cyclosporin A incorporated in liposomes and mixed micelles. Int. J. Pharm. 191:1999;87-93.
19. Lindholm A., Henricsson S., Lind M., Dahlqvist R. Intra-individual variability in the relative availability of cyclosporin after oral dosing. Eur. J. Clin. Pharmacol. 34:1988;461-464.
20. Lueßen H.L., Rentel C.O., Kozté A.F., Lehr C.M., Boer A.G., Verhoef J.C., Junginger H.E. Mucoadhesive in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosa in vitro. J. Control. Release. 45:1997;15-23.
21. Luke D.R., Kasiske B.L., Matzke G.R., Awni W.M., Keane W.F. Effect of cyclosporin on the isolated perfused rat kidney. Transplantation. 43:1987;795-799.
22. Madara J.L. Intestinal absorptive cell tight junctions are linked to cytoskeleton. Am. J. Physiol. 253:1987;C171-C175.
23. Matzke G.R., Luke D.R. Dialysis and renal transplant therapy. Herfindal E.T., Gourley D.R., Hart L.L., Clinical Pharmacy and Therapeutics. 1988;229-242 Williams & Wilkins, Baltimore.
24. Molpeceres J., Guzmán M., Aberturas M.R., Chacon M., Berges L. Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement. J. Pharm. Sci. 85:1996;206-213.
25. Molpeceres J., Guzmán M., Bustamanate P., Aberturas M.R. Exothermic-endothermic heat of solution shift of cyclosporin A related to poloxamer 188 behavior in aqueous solutions. Int. J. Pharm. 130:1996;75-81.
26. Niwa T., Takeuchi H., Hino T., Kunou N., Kawashima Y. Preparation of biodegradable nanospheres of water-soluble and insoluble drugs with D,L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J. Control. Release. 25:1993;89-98.
27. Ptachcinski R.J., Venkataramanan R., Burckart G.J. Clinical pharmacokinetics of cyclosporin. Clin. Pharmacokinet. 11:1986;107-132.
28. Richardson C., Emery P. Clinical use of cyclosporin in rheumatoid arthiritis. Drugs. 50:(suppl. 1):1995;26-36.
29. Rojanasakul Y., Wang L.Y., Bhat M., Glover D.D., Malagna C.J., Ma J.K.H. The transport barrier of epithelia: a comparative study on membrane permeability and charge selectivity in the rabbits. Pharm. Res. 9:1992;1029-1034.
30. Sajjadi H., Soheilian M., Ahmadieh H., Hussanein K., Parvin M., Azarmina M., Ehyaee V., Amiransari B. Low dose cyclosporin-A therapy in Behcet's disease. J. Ocul. Pharmacol. 10:1994;553-560.
31. Schipper N.G.M., Olsson S., Hoogstraate J.A., Boer A.G., Varum K.M., Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm. Res. 14:1997;923-929.
32. Taylor N.E., Mark A.E., Vollat P., Brunne R.M., Testa B., Van Gunteren W.F. Solvent dependent conformation and hydrogen bonding capacity of cyclosporin A: evidence from partition coefficient and molecular dynamic simulations. J. Med. Chem. 36:1993;3753-3764.
33. Teixeira H., Dubernet C., Puisieux F., Benita S., Couvreux P. Submicron cationic emulsions as a new delivery system for oligonucleotides. Pharm. Res. 16:1999;30-36.
34. Tjai J.F., Webber I.R., Back D.J. Cyclosporin metabolism by the gastrointestinal mucosa. Br. J. Clin. Pharmacol. 31:1991;344-346.
35. Urata T., Arimori K., Nakano N. Modification of the release rate of cyclosporin A from Polyl(L-lactic acid) microspheres by fatty acid ester and in vivo evaluation of the microspheres. J. Control. Release. 58:1999;133-141.
36. Venkataram S., Awni W.M., Jordan K., Rahman Y.E. Pharmacokinetics of two alternative dosage forms of cyclosporin: liposomes and intralipid. J. Pharm. Sci. 79:1990;216-219.
37. Yanagawa A., Iwayama T., Saotome T., Shoji Y., Takano K., Oka H., Nakagawa T., Mizushima Y. Selective transfer of cyclosporin to thoracic lymphatic systems by the application of lipid microspheres. J. Microencapsulation. 6:1989;161-164.
38. Zeevi A., Klang S., Alard V., Brossard F., Benita S. The design and characterization of a positively charged submicron emulsion containing a sunscreen agent. Int. J. Pharm. 108:1994;57-68.
39. Zhang Q., Yie G., Li Y., Yang Q., Nagai T. Studies on the cyclosporin A loaded stearic acid nanoparticles. Int. J. Pharm. 200:2000;153-159.